NASDAQ:CMMB Chemomab Therapeutics (CMMB) Stock Price, News & Analysis $3.32 +0.04 (+1.22%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$3.25 -0.07 (-2.08%) As of 04:09 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Chemomab Therapeutics Stock (NASDAQ:CMMB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Chemomab Therapeutics alerts:Sign Up Key Stats Today's Range$3.11▼$3.3750-Day Range$2.50▼$3.8352-Week Range$2.39▼$9.84Volume186,676 shsAverage Volume273,892 shsMarket Capitalization$17.16 millionP/E RatioN/ADividend YieldN/APrice Target$26.50Consensus RatingHold Company Overview Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development. Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes. Its lead oncology programs employ novel bispecific formats intended to engage immune effector cells against solid tumors, while infectious disease programs focus on broad-spectrum neutralization of viral pathogens. Chemomab’s inflammatory disease efforts seek to modulate autoimmune pathways through highly selective receptor blockade. Headquartered in Shanghai with a presence in the United States, Chemomab fosters global collaboration with academic institutions and contract research organizations. The company was founded by a team of immunology and protein engineering experts and is led by a management group with extensive experience in biotechnology R&D and regulatory affairs. Through strategic partnerships and disciplined clinical development, Chemomab Therapeutics is positioning itself to address significant unmet medical needs in multiple therapeutic areas.AI Generated. May Contain Errors. Read More Chemomab Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCMMB MarketRank™: Chemomab Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 577th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingHold Consensus RatingChemomab Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialChemomab Therapeutics has a consensus price target of $26.50, representing about 698.2% upside from its current price of $3.32.Amount of Analyst CoverageChemomab Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Chemomab Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Chemomab Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.70) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chemomab Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chemomab Therapeutics is -1.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChemomab Therapeutics has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Chemomab Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.04% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 14.75%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChemomab Therapeutics does not currently pay a dividend.Dividend GrowthChemomab Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.04% of the float of Chemomab Therapeutics has been sold short.Short Interest Ratio / Days to CoverChemomab Therapeutics has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chemomab Therapeutics has recently increased by 14.75%, indicating that investor sentiment is decreasing significantly. News and Social MediaN/ANews SentimentN/A Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Chemomab Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders11.91% of the stock of Chemomab Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions46.05% of the stock of Chemomab Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chemomab Therapeutics' insider trading history. Receive CMMB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chemomab Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMMB Stock News HeadlinesChemomab Therapeutics (NASDAQ:CMMB) Upgraded by Wall Street Zen to "Hold" RatingOctober 11, 2025 | americanbankingnews.comChemomab Therapeutics management to meet with MaximSeptember 12, 2025 | msn.comGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real opportunity isn’t in coins or bullion. In every major gold rally of the past 50 years, there’s been another investment that has delivered dramatically higher returns. | Weiss Ratings (Ad)Chemomab Therapeutics price target raised to $25 from $10 at OppenheimerAugust 28, 2025 | msn.comChemomab Therapeutics Ltd – ADR trading halted, news pendingAugust 26, 2025 | msn.comChemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 21, 2025 | globenewswire.comCMMB, with P&G Support, Responds to Deadly Cholera and Hunger Crisis in South SudanAugust 14, 2025 | globenewswire.comChemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | globenewswire.comSee More Headlines CMMB Stock Analysis - Frequently Asked Questions How have CMMB shares performed this year? Chemomab Therapeutics' stock was trading at $7.24 at the beginning of the year. Since then, CMMB stock has decreased by 54.1% and is now trading at $3.32. How were Chemomab Therapeutics' earnings last quarter? Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) issued its earnings results on Thursday, August, 14th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.80) by $0.44. When did Chemomab Therapeutics' stock split? Chemomab Therapeutics shares reverse split before market open on Tuesday, August 26th 2025.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. How do I buy shares of Chemomab Therapeutics? Shares of CMMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Chemomab Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chemomab Therapeutics investors own include Arista Networks (ANET), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW), NVIDIA (NVDA), Meta Platforms (META) and Adobe (ADBE). Company Calendar Last Earnings8/14/2025Today10/20/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMMB CIK1534248 Webwww.chemomab.com Phone972-77-331-0156FaxN/AEmployees20Year Founded2010Price Target and Rating Average Price Target for Chemomab Therapeutics$26.50 High Price Target$28.00 Low Price Target$25.00 Potential Upside/Downside+698.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-94.71% Return on Assets-76.53% Debt Debt-to-Equity RatioN/A Current Ratio7.42 Quick Ratio7.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.87 per share Price / Book1.16Miscellaneous Outstanding Shares5,170,000Free Float4,557,000Market Cap$17.16 million OptionableNot Optionable Beta0.57 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CMMB) was last updated on 10/20/2025 by MarketBeat.com Staff From Our PartnersGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredThis Crypto Is Set to Explode in JanuaryCurious about crypto but still stuck scrolling endless threads? People who get in early aren’t just lucky—they...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCould this strange machine change society forever?A mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredAI's Next Magnificent SevenThe original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chemomab Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Chemomab Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.